Liver iron depletion and toxicity of the iron chelator Deferiprone (L1, CP20) in the guinea pig

BioMetals

Volumn 10, Issue 4, 1997, Pages 247-256

  Wong, A ^a   Alder, V ^c   Robertson, D ^a   Papadimitriou, J ^d   Maserei, J ^e   Berdoukas, V ^b   Kontoghiorghes, G ^f   Taylor, E ^a   Baker, E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d PATHWEST LABORATORY MEDICINE   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Carbonyl iron; Deferiprone (L1); Guinea pig; Iron; Iron chelators; Iron overload

Indexed keywords

CARBONYL IRON; DEFERIPRONE; HEME; IRON;

A WAVE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE NECROSIS; CONTROLLED STUDY; DEPLETION; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EYE DISEASE; GUINEA PIG; HEART MUSCLE NECROSIS; IRON CHELATION; IRON OVERLOAD; LEUKOCYTE COUNT; LIVER; LIVER NECROSIS; MALE; MORTALITY; MUSCLE NECROSIS; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; AUDITORY THRESHOLD; BEHAVIOR, ANIMAL; BLOOD CELL COUNT; BODY WEIGHT; DRUG MONITORING; ELECTROLYTES; ELECTRORETINOGRAPHY; ENZYMES; GUINEA PIGS; IRON; IRON CHELATING AGENTS; IRON, DIETARY; LIVER; MYOCARDIUM; NECROSIS; ORGANOMETALLIC COMPOUNDS; PYRIDONES;

EID: 0030688026     PISSN: 09660844     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018312113969     Document Type: Article

References (41)

1. 1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Brit J Hematol 82, 460-466.
2. Albera R, Pia F, Morra B, et al. 1988 Hearing loss and desferrioxamine in homozygous beta-thalassemia. Audiology 27, 207-214.
3. Aldouri MA, Wonke B, Hoffbrand AV, et al. 1987 Iron state and hepatic disease in patients with thalassemia major; treated with long term subcutaneous desferrioxamine. J Clin Pathol 40, 1353-1359.
4. 1) in thalassemia major. Blood 80, 593-599.
5. 1) therapy: a report by the International Study Group on oral iron chelators. Br J Haematol 91, 224-229.
6. Baker E. 1988 Biological screens for iron chelators. In: Thalassemia: Pathophysiology and Management. New York Alan R. Liss Inc. March of Dimes Birth Defects Foundation, Original Article Series: 23(5b): 49-62.
7. Baker E, Richardson DR, Gross S, et al. 1987 Evaluation of new iron chelators in the hepatocyte in culture. Eighth International Conference on Proteins of Iron Transport and Storage, 143 Montreal, P. Ponkan, McGill University.
8. 1) II: Clinical observations. Brit J Hematol 76, 301-304.
9. Ben Nun J, Alder VA, Cringle SJ, Constable, IJC. 1988 A new method for oxygen supply to acute ischemic retina. Invest Ophthalmol & Vis Sci 29, 298-304.
10. Blake DR, Winyard P, Lunec J, et al. 1985 Cerebral and ocular toxicity induced by desferrioxamine. Quart J Med 56, 345-355.
11. Bothwell TH, Charlton RW, Cook JD, Finch CA. 1979. Iron Metabolism in Man. Oxford: Blackwell Scientific Publications.
12. Chan BE, Roeser HP, Nikles AC. 1989 Cytosolic ferritin and lipid-associated ferritin are metabolically different in guinea-pig livers. Biochem J 263, 989-992.
13. Chan BE, Roeser HP, Nikles C. 1990 Ascorbin acid deficiency affects the metabolism of cytosolic ferritin but not lipid-associated ferritin in livers of guinea pigs. Biochem J 267, 535-537.
14. de Virgillis S, Congia M, Frau F, et al. 1988 Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 113, 661-669.
15. 1. Lancet 341, 1088-1089.
16. Hershko C. 1994 Iron chelators. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron Metabolism in Health and Disease. 391-426 London, W.B. Saunders Co. Ltd.
17. Hershko C, Cohen H, Zajicek G. 1976 Iron mobilisation in the pregnant rat. Br J Hematol 33, 505-516.
18. Hider RC, Hall AD. 1991 Iron chelating agents in medicine: the application of bidentate hydroxypyridin-4-ones. Perspectives on Bioinorg Chem 1, 209-253.
19. Kontoghiorghes GJ. 1986 Orally active alpha-ketohydroxypyridine iron chelators: studies in mice. Mol Pharmacol 30, 670-673.
20. 1 (Deferiprone) and other chelators. Analyst 120, 845-851.
21. Kontoghiorghes GJ, Hoffbrand AV. 1986 Orally active a-ketohydroxypyridine iron chelators intended for clinical use: in vivo studies in rabbits. Br J Hematol 62, 607-613.
22. Kontoghiorghes GJ, Sheppard L. 1987 Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones. Inorganica Chimica Acta 136, L11-L12.
23. 1). Br Med J Clin Res 295, 1509-1512.
24. 1): Iron chelation and metabolic studies. Brit J Hematol 76, 295-300.
25. Kontoghiorghes GJ, Barr J, Nortey P, Sheppard L. 1993a Selection of a new generation of orally active a-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload. Am J Hematol 42, 340-349.
26. 1). Lancet 341, 1479-1480.
27. Lipschitz DA, Bothwell TH, Seftel HC, et al. 1991 The role of ascorbic acid in the metabolism of storage iron. Br J Hematol 20, 155-163.
28. Modell B, Berdoukas V. 1984 The Clinical Approach to Thalassemia. New York: Grune & Stratton, Inc.
29. 1 and desferrioxamine in iron-loaded patients. Lancet 336, 1275-1279.
30. 1) in iron-loaded patients. Ann NY Acad Sci USA 612, 369-377.
31. 1 in thalassemia-intermedia. Blood 79, 2741-2748.
32. Park CH, Bacon BR, Brittenham EM, Tavill AS. 1987 Pathology of dietary carbonyl iron overload in rats. Lab Invest 57, 555-563.
33. Pippard MJ, Jackson MJ, Hoffman K, et al. 1986 Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Scand J Hematol 36, 466-472.
34. Porter JB, Huehns ER. 1989 The toxic effects of desferrioxamine. Baillieres' Clin Hematol 2, 459-474.
35. Porter JB, Morgan J, Hoyes KP, et al. 1990 Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 76, 2389-2396.
36. Porter JB, Hoyes KP, Abeysinghe RD, et al. 1991 Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice. Blood 78, 2727-2734.
37. Porter JB, Abeysinghe RD, Hoyes KP, et al. 1993 Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site. Br J Hematol 85, 159-168.
38. Robertson D, Wilson SA. 1991 Changes in cochlear sensitivity do not alter relative thresholds of different spontaneous rate categories of primary auditory nerve fibres. Hearing Res 51, 29-32.
39. Singh S, Epemolu RO, Dobbin PS, et al. 1992 Urinary metabolic profiles in human and rat of 1,2-dimethyl-substituted and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones. Drug Metabolism and Disposition 20, 256-261.
40. Torrance JD, Bothwell TH. 1968 A simple technique for measuring storage iron concentrations in formalised liver samples. S Afr J Med Sci 33, 9-11.
41. Ward C, Saltman P, Ripley L, et al. 1977 Correlation of serum ferritin and liver ferritin iron in the anemic, normal and iron-loaded rat. Am J Clin Nutr 30,